How to deal with gene therapy’s evidence problem

Little long-term data exists on gene therapy's effectiveness and downstream risks, including unforeseen malignancies. New evidence pathways could support coverage. 

April 30, 2024 Check out STAT+

Sponsored By

Dom Smith/STAT STAT+ | New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis, STAT has learned. By Adam Feuerstein STAT+ | Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion Deciphera markets Qinlock, a drug for patients with advanced gastrointestinal stromal tumors, or GIST, a type of cancer that begins in the digestive system. By Adam Feuerstein STAT+ | House bill aimed at Chinese biotechs is advancing  Today's biotech news includes concern over the safety of pelabresib, an experimental treatment made by MorphoSys. By Meghana Keshavan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser